MagDI vs Sleeve Gastrectomy

Sleeve gastrectomy is one of the most studied bariatric procedures in the world. MagDI is a newer technology that creates a duodeno-ileal anastomosis using magnetic compression. The two are not mutually exclusive — Sleeve Plus combines them.

Written by MagnaMetabolic Editorial Team Medically reviewed by Ariel Ortiz, MD — Bariatric & Metabolic Surgery Last reviewed: June 7, 2026

Mechanism

Sleeve gastrectomy: permanent removal of a portion of the stomach, reducing capacity and altering gut hormones.
MagDI: creation of a duodeno-ileal anastomosis using two self-aligning magnets that detach and pass naturally; no foreign material remains at the site.

Evidence base

Sleeve gastrectomy has decades of large, long-term data and is endorsed by ASMBS/IFSO guidance.
MagDI has FDA De Novo (2024) and 510(k) clearances and growing peer-reviewed publications; long-term comparative data remain limited.

How they are used together

Sleeve Plus and Sleeve Plus MagDI combine the established restrictive sleeve gastrectomy with the newer MagDI anastomosis to add a metabolic component. Choice depends on patient goals, anatomy, and clinical judgment.

Evidence

Scientific References

Selected primary sources informing this page. External links open in a new tab; we do not control or endorse third-party content.

ASMBSAmerican Society for Metabolic and Bariatric Surgery (ASMBS) and IFSO 2022 indications for metabolic and bariatric surgery.
Obesity SurgeryGagner M, et al. First-in-human experience of magnetic duodeno-ileostomy for the treatment of obesity and metabolic disease. Obesity Surgery.
Surgical EndoscopyMulti-center early outcomes of sleeve gastrectomy combined with magnetic duodeno-ileostomy (Sleeve Plus MagDI). Surgical Endoscopy.
FDAU.S. FDA — De Novo Classification DEN240013: MagDI System (Magnetic Duodeno-Ileostomy), De Novo marketing authorization granted July 2, 2024.
FDAU.S. FDA — 510(k) Premarket Notification K242086: MagDI System (second generation), clearance granted October 24, 2024.